Arda Therapeutics

Arda’s founders, CEO Adam Freund and CTO Remi-Martin Laberge, joined the Translating Aging podcast with host Chris Patil to explore their cutting-edge approach to treating chronic diseases. Adam and Remi discussed Arda’s origin and shared how Arda's single-cell-based discovery platform pinpoints pathogenic cells in conditions like fibrosis, allowing for targeted cell depletion instead of traditional pathway modification. They described the challenges and opportunities inherent to applying the immune-oncology toolbox to non-oncology diseases, and outlined their vision for antibody-based therapeutics that could offer long-lasting effects with intermittent dosing, improving patient quality of life and paving the way for future applications in aging.

Thanks to our new investors at Two Sigma Ventures for this excellent write-up. We are excited to work with you!

Arda is pleased to announce the closing of our $43M Series A financing to accelerate the development of precision cell-depleting biologics to treat chronic diseases. The new capital will be used to drive our existing I&I pipeline toward the clinic, expand into new indications, and scale our single cell discovery platform. Thank you to our investors Andreessen Horowitz, Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV (Google Ventures), Biovision Ventures, Valhalla Ventures, Indicator Ventures, Alumni Ventures, LifeLink Ventures, Mana Ventures, Gaingels, and Exitfund. Learn more about our mission to deplete pathogenic cells to treat disease at www.ardatx.com!

We're #hiring a new Research Associate, In vivo pharmacology in San Carlos, California. Apply today or share this post with your network.

We're #hiring a new Research Associate/Senior Research Associate, Cell Biology in San Carlos, California. Apply today or share this post with your network.

We're #hiring a new Research Associate/Senior Research Associate, Protein Science in San Carlos, California. Apply today or share this post with your network.

Arda is proud to participate in the upcoming Annual IPF Summit. Arda Founder and CEO Adam Freund will highlight our exciting progress depleting pathogenic cells to treat pulmonary fibrosis.

We're thrilled to welcome Scott Turner as the new Chief Scientific Officer at Arda. Scott brings with him a wealth of experience and expertise, particularly in the development and translation of anti-fibrotic therapies. Prior to joining us, Scott served as CSO at Pliant Therapeutics, where he played a pivotal role in the creation of Pliant's fibrosis discovery platform and the development of their anti-fibrotic pipeline. His innovative approaches, including applying single-cell precision cut tissue slice data to dissect drug mechanisms of action and driving an advanced biomarker strategy, led to remarkable successes in achieving clinical proof of concept. With Scott at the helm as our new CSO, we're confident that his expertise will be instrumental in advancing our lead programs towards the clinic and driving innovative approaches to achieve pathogenic cell depletion. Join us in extending a warm welcome to Scott as he embarks on this new journey with Arda! #Leadership #Innovation #CSO #Biotech #Fibrosis

We are thrilled to announce the much-deserved promotion of Arda co-founder Remi-Martin Laberge to Chief Technology Officer. Remi has been an invaluable asset to our team since the beginning, consistently demonstrating exceptional leadership,?scientific acumen, and a relentless drive for innovation. Remi's vision and dedication will?continue to?be instrumental in accelerating our development of medicines that deplete the pathogenic cell populations that drive chronic diseases. We are excited for the future of Arda under his leadership as CTO, and we look forward to achieving even greater success together! #Leadership #Innovation #Promotion #CTO #Biotech

We're #hiring a new Scientist in San Carlos, California. Apply today or share this post with your network.